Metabolon Enters into Collaboration with GSK

  Metabolon Enters into Collaboration with GSK

Business Wire


Metabolon, Inc., a leading diagnostics and research services company offering
metabolomics research platforms, has entered into a collaboration with
GlaxoSmithKline (GSK) to provide metabolomic profiling services and to
collaborate on other research projects leveraging Metabolon’s leading
DiscoveryHD4™ platform.

The collaboration will give GSK access to Metabolon’s bioinformatics tools
along with the company’s proprietary disease ontologies, as well as
visualization tools that will integrate metabolomics data with existing
genomics and proteomics data. John Ryals, Metabolon President and CEO
commented, “We are pleased to announce a collaboration with GSK. We believe
that embedding metabolomic profiling capabilities at the various stages of R&D
is important to enhance the phenotypic ‘picture’ with the aim of yielding
translatable, meaningful results. Gaps of knowledge can be bridged through the
understanding metabolomics provides, which could lead to better targets,
higher quality molecules, faster time to the clinic and reduced risk and

Metabolon, Inc. has completed thousands of metabolomics studies across
numerous therapeutic areas and has developed expertise in metabolic pathways
and targets that are involved in the onset of disease and its progression.
Metabolon’s technology platforms are robust and known for their rapid,
repeatable results. Expert, credentialed biochemists interpret biological data
to yield actionable insight into key disease metabolic processes, drug action,
and patient response.

About Metabolon

Metabolon is a world-leading, commercial-stage metabolomics company.
Metabolomics is a rapidly evolving field of biochemical research and discovery
focused on the measurement of small molecules involved in metabolism.
Metabolon’s proprietary metabolomics technology maps these small molecule
pathways to identify diseases, discover biomarkers, and better understand
complex biological processes. The company’s Metabolytics business uses its
proprietary metabolomics technology to conduct sponsored studies for life
sciences researchers in industry and academia, which provide insight into
complex biochemical processes. Data from these studies are used to populate
Metabolon’s large and growing metabolomic information and pathway knowledge
databases, which generate new product ideas for the company’s Diagnostics
business. For more information, visit, or email or call 919-287-3364.

Metabolon Cautionary Note about Forward-Looking Statements

The materials provided herein that are not historical facts are or might
constitute projections and other forward-looking statements regarding future
events that involve substantial risks, uncertainties, and assumptions. If any
of these risks or uncertainties materializes or if any of these assumptions
prove incorrect, the results of Metabolon could differ materially from the
results expressed or implied by any forward-looking statements. The risks,
uncertainties, and assumptions referred to above include, but are not limited
to: the uncertainties inherent in biochemical research and development;
decisions by regulatory authorities regarding whether and when to approve
diagnostic tests; our and our partners’ ability to successfully commercialize
and market both new and existing products; governmental laws and regulations
affecting health care, including regarding access, pricing and reimbursement
of diagnostic tests; the strength of our intellectual property portfolio; our
history of losses; whether we are able to achieve or sustain profitability;
our highly competitive industry; our ability to compete effectively; security
and privacy risks; and our ability to continue to innovate and provide
products and services that are useful to our clients, among other risks,
uncertainties, and assumptions.


John Ryals, 919-287-3364
Press spacebar to pause and continue. Press esc to stop.